On August 15, 2019, the Court of Appeals for the Federal Circuit ruled in favor of Venable Fitzpatrick's client, Nalpropion Pharmaceuticals, Inc., and against Actavis Laboratories FL, Inc., affirming the District Court's holding that claim 11 of U.S. Patent No. 8,916,195 is not invalid for lack of written description. The '195 patent covers the use of Nalpropion's Contrave product to treat overweight or obesity. Actavis was seeking to market a generic version of Contrave prior to the expiration of the '195 patent. The decision means that Actavis will be prevented from launching its generic version until February 2030, when the '195 patent expires
Nalpropion was represented by Venable Fitzpatrick attorneys Dominick Conde, Chris Borello, Fred Millett, Josh Calabro, and Zachary Garrett.